权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Flow cytometric evaluation of biomarkers

生物标志物的流式细胞术评估

基本信息

批准号：
10926620
负责人：
Hao-Wei Wang
金额：
$ 57.14万
依托单位：
DIVISION OF BASIC SCIENCES - NCI
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10926620
关键词：
Antibodies Antibody Therapy Antigens B-Cell Lymphomas Benign Binding Biological Assay Biological Markers CAR T cell therapy CCR Cell Surface Proteins Cells Characteristics Clinical Development Diagnosis Disease Evaluation Flow Cytometry Fluorescent Antibody Technique Goals HIV/AIDS Human Herpesvirus 8 Institution Lymphoproliferative Disorders Malignant Neoplasms Medical Monitor Neoplasms Pathway interactions Patients Play Population Research Research Personnel Resources Role Sampling Site Stains System Techniques Testing Therapeutic Therapeutic Agents Therapeutic antibodies Time biomarker evaluation cancer cell cell determination chimeric antigen receptor T cells improved insight neoplastic cell new technology novel therapeutics primary effusion lymphoma prognostication rapid test response therapeutic evaluation therapeutic target treatment response

项目摘要

Clinical quantitative flow cytometry is a new technology that utilizes specialized antibody staining techniques and fluorescent standards to quantitate antigen expression by different cell populations within a sample. The Flow Cytometry Unit uses this technique to quantitate tumor cell antigen expression in patients undergoing various antigen directed therapies (e.g. therapeutic antibody, CAR T-cell therapy). The flow cytometric assays are rapid and very precise. This improves the ability of NCI investigators to monitor decrease or increase in antigen expression, as well as compare antibody binding to tumor cells to treatment response. Quantitation of fluorescent antibody binding immediately post therapy also allows precise determination of saturation of antigen sites with non labeled therapeutic antibody. Quantitation of antigens prior to, during and post therapy may provide insight into pathways disrupted by novel therapeutic agents. Antigen Quantitation is therefore a tremendous resource for NCI investigators that is not available at other institutions. Flow cytometric testing is also utilized to evaluate patients receiving chimeric antigen receptor (CAR) T cell therapy at NCI. It plays a vital role in assessing response to chimeric antigen receptor (CAR) T cell therapy by quantitating expansion of the therapeutic CAR T cells in the patient while at the same time monitoring the decrease in neoplastic cells. Additionally, the Flow Cytometry Unit also continues to support ongoing research in the CCR HIV and AIDS Malignancy Branch, including development of new biomarker assay, such as LANA1 flow cytometric assay, for evaluation of HHV8-associated B-cell lymphoma or lymphoproliferative disorders, and evaluation of potential therapeutic target, such as CD38, for primary effusion lymphoma.

临床定量流式细胞术是一种新技术，其利用专门的抗体染色技术和荧光标准品来定量样品中不同细胞群的抗原表达。流式细胞术单元使用该技术定量接受各种抗原导向疗法（例如治疗性抗体、CAR T细胞疗法）的患者中的肿瘤细胞抗原表达。流式细胞术检测快速且非常精确。这提高了NCI研究人员监测抗原表达减少或增加的能力，以及将抗体与肿瘤细胞的结合与治疗反应进行比较。在治疗后立即定量荧光抗体结合还允许精确测定抗原位点与未标记的治疗性抗体的饱和度。在治疗前、治疗期间和治疗后对抗原进行定量可提供对被新型治疗剂破坏的途径的了解。因此，抗原定量是NCI研究人员的一个巨大资源，这是其他机构所无法获得的。流式细胞术检测也用于评估在NCI接受嵌合抗原受体（CAR）T细胞治疗的患者。它通过定量患者中治疗性CAR T细胞的扩增，同时监测肿瘤细胞的减少，在评估对嵌合抗原受体（CAR）T细胞治疗的反应中起着至关重要的作用。此外，流式细胞术组亦继续支援中央癌症研究中心爱滋病病毒及爱滋病病毒科分支进行中的研究，包括开发新的生物标记物分析方法，例如LANA1流式细胞术分析方法，以评估与HHV 8相关的B细胞淋巴瘤或淋巴增生性疾病，以及评估原发性渗出性淋巴瘤的潜在治疗靶点，例如CD 38。

项目成果

期刊论文数量（35）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.

DOI：
10.3109/10428194.2011.565843
发表时间：
2011-06
期刊：
Leukemia & lymphoma
影响因子：
2.6
作者：
Kreitman RJ;Arons E;Stetler-Stevenson M;Fitzgerald DJ;Wilson WH;Pastan I
通讯作者：
Pastan I

Visual inspection versus quantitative flow cytometry to detect aberrant CD2 expression in malignant T cells.

DOI：
10.1002/cyto.b.20507
发表时间：
2010-05
期刊：
CYTOMETRY PART B-CLINICAL CYTOMETRY
影响因子：
3.4
作者：
Arun, Indu;Wulu, Jacqueline A.;Janik, John E.;Jasper, Gregory A.;Yuan, Constance M.;Venzon, David;Stetler-Stevenson, Maryalice
通讯作者：
Stetler-Stevenson, Maryalice

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

DOI：
10.1158/1078-0432.ccr-15-1304
发表时间：
2016-01-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
0
作者：
Skarzynski M;Niemann CU;Lee YS;Martyr S;Maric I;Salem D;Stetler-Stevenson M;Marti GE;Calvo KR;Yuan C;Valdez J;Soto S;Farooqui MZ;Herman SE;Wiestner A
通讯作者：
Wiestner A

Response of hairy cell leukemia to bendamustine.

毛细胞白血病对苯达莫司汀的反应。